CID S.p.A.
7 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| RADIX 2 RENAL STENT Post-Market Retrospective Study (NCT05612438) | CID S.p.A. | 2023-03-03 |
| The Cre8™ BTK Post Market Clinical Follow-up Study (NCT05616156) | CID S.p.A. | 2023-02-01 |
| The EasyFlype/EasyHiFlype Post Market Clinical Follow-up Study. (NCT05616169) | CID S.p.A. | 2023-02-01 |
| The Isthmus Logic Post Market Clinical Follow-up Study (NCT05616143) | CID S.p.A. | 2023-02-01 |
| The Inperia Advance Post-Market Retrospective Study (NCT05622084) | CID S.p.A. | 2023-02-01 |
| Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions (NCT02360709) | CID S.p.A. | 2014-11-01 |
| Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions (NCT02360423) | CID S.p.A. | 2014-11-01 |
Track CID S.p.A. automatically
Every clearance here is in the API, with alerts when new ones post.